Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$23.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $139.5M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$911M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1.0%
↑Gross Margin
N/A
•Debt/Equity
0.54
↑Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+27.4%
FCF CAGR
—
FCF margin
18.8%
FCF / Net income
19.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $726.4M · net income $7.0M · FCF $136.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $726.4M | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M | $429.6M | $418.9M | $332.4M | $284.3M | $270.1M | $249.0M | $197.7M | $85.6M | $39.1M | $15.7M | $14.6M | $15.0M |
| Net Income | $7.0M | $7.0M | $-99.6M | $42.0M | $15.9M | $42.0M | $145.5M | $-11.0M | $-471000.00 | $-42.6M | $-37.9M | $1.9M | $-13.7M | $-63.9M | $-52.3M | $-43.3M | $-27.1M | $-31.7M |
| EBITDA | $110.2M | $110.2M | $5.4M | $163.2M | $151.5M | $118.5M | $66.3M | $30.1M | $29.1M | $-11.1M | $-19.1M | $20.9M | $4.9M | $-47.5M | $-43.6M | $-34.8M | $-18.6M | $-24.4M |
| EPS | 0.16 | 0.16 | -2.15 | 0.89 | 0.34 | 0.92 | 3.33 | -0.27 | -0.01 | -1.07 | -1.02 | 0.04 | -0.39 | -1.93 | — | — | — | — |
| Operating Margin | 2.6% | 2.6% | -10.5% | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.8% | -8.8% | -11.9% | 3.8% | -2.6% | -62.3% | -126.1% | -249.2% | -155.9% | -190.2% |
| Net Margin | 1.0% | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -15.0% | -14.1% | 0.7% | -6.9% | -74.7% | -133.8% | -276.2% | -186.4% | -211.3% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.54 | 0.54 | 0.49 | 0.60 | 0.89 | — | — | — | — | — | 0.50 | 0.48 | 0.60 | 0.00 | 0.38 | 0.38 | -0.45 | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $136.7M | $136.7M | $178.8M | $139.5M | $115.2M | $79.9M | $39.2M | $60.4M | $34.4M | $-1.5M | — | — | — | — | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | 1.0% | 1.0% | -12.8% | 4.8% | 2.1% | 5.7% | 23.5% | -3.1% | -0.1% | -15.2% | -17.3% | 0.8% | -8.0% | -154.9% | -79.4% | -89.8% | 56.1% | 138.2% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 3.6% | 3.6% | 3.9% | 1.2% | 23.1% | 26.0% | 2.6% | 26.0% | 16.9% | 5.3% | 8.5% | 26.0% | 131.1% | 118.9% | 149.1% | 7.7% | -3.0% | — |
| EPS Growth | 107.4% | 107.4% | -341.6% | 161.8% | -63.0% | -72.4% | 1333.3% | -2600.0% | 99.1% | -4.9% | -2650.0% | 110.3% | 79.8% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
134.2%
EPS terminal req.
$2.05
Spread vs growth
-26.7%
5Y implied EPS CAGR
73.1%
EPS terminal req.
$2.49
Spread vs growth
34.4%
10Y implied EPS CAGR
38.0%
EPS terminal req.
$4.00
Spread vs growth
69.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.